BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities
Details
Publication Year 2024-09,Volume 23,Issue #3,Page 215-229
Journal Title
Clinical Colorectal Cancer
Publication Type
Review
Abstract
BRAF(V600E)-mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard therapies, and poor survival rates. Improved understanding of the biology of the BRAF oncogene has led to the development of targeted therapies that have paved the way for a paradigm shift in managing this disease. However, despite significant recent advancements, responses to targeted therapies are short-lived, and several challenges remain. In this review, we discuss how progress in treating BRAF(V600E)-mutant metastatic colorectal cancer has been made through a better understanding of its unique biological and clinical features. We provide an overview of the evidence to support current treatment approaches and discuss critical areas of need and future research strategies that hold the potential to refine clinical practice further. We also discuss some challenging aspects of managing this disease, particularly the complexity of acquired resistance mechanisms that develop under the selective pressure of targeted therapies and rational strategies being investigated to overcome them.
Publisher
Elsevier
Keywords
Humans; *Proto-Oncogene Proteins B-raf/genetics; *Colorectal Neoplasms/genetics/pathology/therapy/drug therapy; *Mutation; *Molecular Targeted Therapy/methods; Drug Resistance, Neoplasm/genetics; Neoplasm Metastasis; Bowel cancer; MAPK pathway; Predictive biomarkers; Resistance mechanisms; Targeted therapy
Department(s)
Medical Oncology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-19 02:59:45
Last Modified: 2024-09-19 03:00:01

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙